Germantown, MD — September 17, 2025 — Leads & Copy — uBriGene Biosciences has launched its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cells (iPSC).
The RNA-LNP-based kit avoids genome integration risks and is optimized for PBMCs, achieving up to 0.31% efficiency in reprogramming PBMCs to iPSCs, enabling the generation of patient-specific iPSCs from just 10 mL of blood, eliminating the risk of immune rejection.
Dr. Xiulian Sun, CTO and Founder of uBriGene Biosciences, stated that the kit combines clinical-grade safety with high performance, accelerating the path from basic research to therapeutic applications.
Founded in 2015, uBriGene Biosciences is a CDMO specializing in advanced therapeutic medicinal products (ATMPs), providing integrated CDMO and CRO solutions covering cell therapy products, viral vectors, RNA-related products, and induced pluripotent stem cell (iPSC) technologies.
Contact Information:
Mingjuan Liu
Director of Marketing
contact@ubrigene.com
800 663 2528
Source: uBriGene Biosciences
